Last reviewed · How we verify
NCT05126810
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
trial testing Questionnaire Administration in Li-Fraumeni Syndrome in 500 participants. Currently enrolling.
2 February 2027
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 3 November 2022 |
| Primary completion | 2 February 2027 |
| Estimated completion | 2 October 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Questionnaire Administration
Conditions studied
- Li-Fraumeni Syndrome — all drugs for Li-Fraumeni Syndrome →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Eligibility, any sex, with Li-Fraumeni Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates patients willingness to participate in a trial comparing standard genetic counseling versus personalized genetic counseling. Collecting information from patients may help researchers learn why patients may or may not take part in the future study that compares standard genetic counseling to personalized genetic counseling.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05126810
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire Administration
Trials testing the same drug.
- NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
- NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
- NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting
- NCT05095948 — Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center · not yet recruiting
- NCT07281547 — Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometr · Phase 4 · not yet recruiting
Other recruiting trials for Li-Fraumeni Syndrome
Currently open trials in the same condition.
- NCT06088030 — Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer · Phase 2 · recruiting
- NCT06523582 — Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients · recruiting
- NCT04541654 — Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress · recruiting
- NCT04367246 — Li-Fraumeni Syndrome/TP53 Biobank · recruiting
- NCT03050268 — Familial Investigations of Childhood Cancer Predisposition · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05126810 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126810.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing